In September 2019, Purdue Pharma reached an agreement to settle the large number of pending claims against their company. Purdue and its subsidiaries decided to file for Chapter 11 bankruptcy, which will help restructure the company, remove the company’s founding family and restrict where and how Purdue Pharma can do business moving forward.
Since 2000, the opioid epidemic has claimed the lives of more than 400,000 Americans. Drug company marketing campaigns and the practices of the Drug Enforcement Administration (DEA) are responsible for over 100 related deaths per day.
Prenatal opioid exposure is a growing public health crisis, yet there has been limited data concerning the effects of opioids on developing children. A recent study presented at the Radiological Society of North America (RSNA) found that prenatal exposure to opioids may alter connectivity in the area of the brain that regulates emotions.
The FDA has approved Invokana to reduce end-stage kidney disease, decreased kidney function, cardiovascular health and heart failure in adult patients living with Type 2 diabetes and diabetic kidney disease (nephropathy). Invokana is an SGLT2 inhibitor associated with amputation and diabetic ketoacidosis risks.